Thus, we used the gene signature (n = 276 genes) characterizing the MITFlow/PTENneg melanomas and created a centroid that was applied on gene expression data derived from patients receiving ICB or BRAF/MEK inhibitors [20,21]. Here, BRAF is linked to melanoma.